title: Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.
abstract: BACKGROUND
  Thiazolidinediones (TZDs) improve peripheral insulin sensitivity, but the effect on arterial stiffness is less clear. The aim of the present study was to assess the differential effect of pioglitazone or rosiglitazone on arterial stiffness and plasma levels of adiponectin and leptin in patients with type 2 diabetes mellitus.
  
  
  METHODS
  Thirty-five type 2 diabetic subjects were randomly assigned to receive pioglitazone (30 mg/day; n = 14), rosiglitazone (4 mg/day; n = 11), or placebo (medical nutrition therapy; n = 10) for 12 weeks. Changes in plasma glucose, glycosylated hemoglobin, insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, adiponectin, and leptin were evaluated at baseline and after 12 weeks. In parallel, large arterial compliance (C1) and small arterial compliance (C2) were measured at baseline and at the end of treatment period.
  
  
  RESULTS
  At 12 weeks, the rosiglitazone (P = 0.026) and pioglitazone (P = 0.004) groups had a significant increase from baseline in adiponectin that was not seen in the medical nutrition therapy group. No significant changes in plasma leptin and in C1 and C2 elasticity indexes were observed over the entire study period in any of the treatment groups.
  
  
  CONCLUSIONS
  In this study of patients with type 2 diabetes, treatment with TZDs was associated with a significant improvement in adiponectin levels, although no significant effects were seen on leptin levels and arterial elasticity.
authors.affiliation: Department of Internal Medicine, Uludag University Medical School, Gorukle, Bursa, 16059, Turkey. ozenoz@uludag.edu.tr
authors.forename: Ozen
authors.initials: O
authors.lastname: Oz
authors.forename: Ercan
authors.initials: E
authors.lastname: Tuncel
authors.forename: Salih
authors.initials: S
authors.lastname: Eryilmaz
authors.forename: Murat
authors.initials: M
authors.lastname: Fazlioglu
authors.forename: Cuma Bulent
authors.initials: CB
authors.lastname: Gul
authors.forename: Canan
authors.initials: C
authors.lastname: Ersoy
authors.forename: Nihal
authors.initials: N
authors.lastname: Ocak
authors.forename: Melahat
authors.initials: M
authors.lastname: Dirican
authors.forename: Sengul
authors.initials: S
authors.lastname: Cangur
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Baran
authors.forename: Sazi
authors.initials: S
authors.lastname: Imamoglu
mesh_terms: D052242:Adiponectin / Q000097:blood*; D001158:Arteries / Q000187:drug effects / Q000502:physiology*; D001786:Blood Glucose / Q000187:drug effects; D015992:Body Mass Index; D002200:Capillary Resistance / Q000187:drug effects / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004548:Elasticity / Q000187:drug effects; D005260:Female; D038321:Glycemic Index / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D020738:Leptin / Q000097:blood*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D010919:Placebos; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D020738:Leptin; D008055:Lipids; D010919:Placebos; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone